Urologie pro praxi 3/2023
Imunoterapie u nádorů ledvin
Malignant kidney tumours are a frequent malignancy, with the Czech Republic having the highest rates of incidence in Europe. Treatment options for this disease have advanced greatly in recent years. Both advances in modern surgical methods and treatment with tyrosine kinase inhibitors (TKIs) have significantly contributed to the decreasing morbidity rates and improved survival rates. Major progress has been achieved with the inclusion of immunotherapy in the treatment regimens for this disease. This article deals with immunotherapy alone, combined immunotherapy, as well as the combination of immunotherapy with TKIs.
Keywords: Immimmunotherapy, combined immunotherapy, checkpoint inhibitors, kidney tumour, RCC, mRCC, kidney tumour treatment.unotherapy in kidney tumours
